332 related articles for article (PubMed ID: 18538733)
1. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M
Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733
[TBL] [Abstract][Full Text] [Related]
2. Linking miRNA regulation to BCR-ABL expression: the next dimension.
Faber J; Gregory RI; Armstrong SA
Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
[TBL] [Abstract][Full Text] [Related]
3. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
5. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
7. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
9. Low expression of miR-196b enhances the expression of BCR-ABL1 and HOXA9 oncogenes in chronic myeloid leukemogenesis.
Liu Y; Zheng W; Song Y; Ma W; Yin H
PLoS One; 2013; 8(7):e68442. PubMed ID: 23894305
[TBL] [Abstract][Full Text] [Related]
10. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
Shibuta T; Honda E; Shiotsu H; Tanaka Y; Vellasamy S; Shiratsuchi M; Umemura T
Leuk Res; 2013 Oct; 37(10):1278-86. PubMed ID: 23953880
[TBL] [Abstract][Full Text] [Related]
11. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
Liu Y; Song Y; Ma W; Zheng W; Yin H
Leuk Res; 2013 Mar; 37(3):349-56. PubMed ID: 23287430
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
13. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
14. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
Wang LQ; Wong KY; Rosèn A; Chim CS
Oncotarget; 2015 Dec; 6(42):44422-36. PubMed ID: 26517243
[TBL] [Abstract][Full Text] [Related]
16. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).
Iacobucci I; Storlazzi CT; Cilloni D; Lonetti A; Ottaviani E; Soverini S; Astolfi A; Chiaretti S; Vitale A; Messa F; Impera L; Baldazzi C; D'Addabbo P; Papayannidis C; Lonoce A; Colarossi S; Vignetti M; Piccaluga PP; Paolini S; Russo D; Pane F; Saglio G; Baccarani M; Foà R; Martinelli G
Blood; 2009 Sep; 114(10):2159-67. PubMed ID: 19589926
[TBL] [Abstract][Full Text] [Related]
17. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
18. The Philadelphia chromosome in leukemogenesis.
Kang ZJ; Liu YF; Xu LZ; Long ZJ; Huang D; Yang Y; Liu B; Feng JX; Pan YJ; Yan JS; Liu Q
Chin J Cancer; 2016 May; 35():48. PubMed ID: 27233483
[TBL] [Abstract][Full Text] [Related]
19. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Yeh CH; Abdool A; Bruey JM
Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
[TBL] [Abstract][Full Text] [Related]
20. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
